{"id":77649,"date":"2011-05-26T10:59:00","date_gmt":"2011-05-26T10:59:00","guid":{"rendered":"https:\/\/novaorg.cofb.net\/2011\/05\/26\/hi-ha-obstacles-terapeutics-que-no-sestan-resolent-per-una-infrautilitzacio-de-la-formulacio-magistral\/"},"modified":"2011-05-26T10:59:00","modified_gmt":"2011-05-26T10:59:00","slug":"hi-ha-obstacles-terapeutics-que-no-sestan-resolent-per-una-infrautilitzacio-de-la-formulacio-magistral","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/ca\/2011\/05\/26\/hi-ha-obstacles-terapeutics-que-no-sestan-resolent-per-una-infrautilitzacio-de-la-formulacio-magistral\/","title":{"rendered":"Hi ha obstacles terap\u00e8utics que no s’estan resolent per una infrautilitzaci\u00f3 de la formulaci\u00f3 magistral"},"content":{"rendered":"

\u00a0<\/p>\n

\u00a0\u2022 Oncologia, pediatria, geriatria i situacions cl\u00edniques complexes troben resposta en el medicament personalitzat a m\u00faltiples<\/span>\u00a0<\/span>llacunes terap\u00e8utiques<\/strong>\u00a0<\/span><\/p>\n

\u2022 De tot aix\u00f2 es va parlar en el\u00a0IV F\u00f2rum Aprofarm<\/strong>, celebrat la passada setmana a Barcelona amb la col\u00b7laboraci\u00f3 del COFB i m\u00e9s de 220 assistents, sota el t\u00edtol \u201cFormulaci\u00f3 de futur: ter\u00e0pies individualitzades\u201d\u00a0<\/p>\n

\u2022 En l\u2019edici\u00f3 d\u2019enguany es va presentar\u00a0el primer Formulari adre\u00e7at a metges d\u2019Atenci\u00f3 Prim\u00e0ria<\/strong>\u00a0amb m\u00e9s de 150 f\u00f3rmules\u00a0<\/p>\n

Barcelona, maig de 2011.- \u201cMolts problemes que es podrien resoldre amb la formulaci\u00f3 magistral no s’estan resolent per desconeixement\u201d. Aix\u00ed ho explica Francesc Llamb\u00ed, president d\u2019Aprofarm, l’associaci\u00f3 de formuladors magistrals que aquest mes de maig ha celebrat la IV edici\u00f3 del F\u00f2rum Aprofarm amb la col\u00b7laboraci\u00f3 del Col\u00b7legi de Farmac\u00e8utics de Barcelona i l’assist\u00e8ncia de m\u00e9s de 220 professionals. L’objectiu: apropar als professionals les solucions terap\u00e8utiques que pot oferir el medicament personalitzat.\u00a0<\/p>\n

En la inauguraci\u00f3 de la trobada, Llamb\u00ed va insistir en la necessitat de mostrar la formulaci\u00f3 magistral com un recurs terap\u00e8utic a utilitzar. Per la seva banda, Jordi De Dalmases, president del Col\u00b7legi de Farmac\u00e8utics de Barcelona, va parlar de la necessitat de \u201ctreballar i acaronar conjuntament la formulaci\u00f3 magistral\u201d. I, en aquest sentit, tots dos van destacar el treball que s’est\u00e0 realitzant des del Consejo General de Colegios Farmac\u00e9uticos amb diversos projectes oberts en el marc del grup de treball del que forma part De Dalmases.\u00a0<\/p>\n

\u201cEl farmac\u00e8utic pot aportar solucions a problemes relacionats amb el subministrament de medicaments en pediatria, geriatria, insufici\u00e8ncies renals i hep\u00e0tiques, situacions cl\u00edniques complicades, problemes de degluci\u00f3, coordinaci\u00f3, malalts terminals\u2026 per\u00f2 per a aix\u00f2 \u00e9s necessari que tant farmac\u00e8utics com metges coneguin el que pot oferir la formulaci\u00f3 magistral\u201d, insisteix Llamb\u00ed.\u00a0<\/p>\n

Amb aquest mateix objectiu es va presentar en el marc del F\u00f2rum el primer formulari dirigit a metges d’atenci\u00f3 prim\u00e0ria, amb m\u00e9s de 150 f\u00f3rmules a les quals accedir per patologia o principi actiu i que poden donar resposta a m\u00faltiples pacients amb necessitats espec\u00edfiques. Un \u201cFormulari b\u00e0sic d’Atenci\u00f3 Prim\u00e0ria\u201d, que ja est\u00e0 disponible a trav\u00e9s de la xarxa [www.cofb.org\/web\/guest\/als-professionals-sanitaris].\u00a0<\/p>\n

A Espanya el volum de dispensacions de f\u00f3rmules magistrals \u00e9s inferior a l\u20191%, lluny de les xifres d’altres pa\u00efsos com Holanda, EUA o Brasil. No obstant aix\u00f2, en \u00e0mbits com les UCIs de neonatologia, entre el 35 i 40% dels medicaments s\u00f3n f\u00f3rmules magistrals. \u201cNo es tracta d’estendre el seu \u00fas de forma indiscriminada per\u00f2 s\u00ed de donar una resposta adequada a aquelles patologies que ho requereixin\u201d, explica Llamb\u00ed. C\u00e0ncer i prec\u00e0ncer cutani, formulaci\u00f3 pedi\u00e0trica, dermatologia i cosm\u00e8tica, podologia, veterin\u00e0ria\u2026 s\u00f3n alguns exemples i sobre tots ells es va parlar en les diferents taules rodones que va acollir la trobada a c\u00e0rrec de m\u00e9s de 25 especialistes de les diverses \u00e0rees.\u00a0<\/p>\n

\u201cLa formulaci\u00f3 magistral est\u00e0 estretament relacionada amb l’Atenci\u00f3 Farmac\u00e8utica\u201d<\/strong><\/p>\n

En les taules rodones es va abordar tamb\u00e9 un nou enfocament: els punts de connexi\u00f3 entre formulaci\u00f3 i atenci\u00f3 farmac\u00e8utica. Amb els medicaments individualitzats l’Atenci\u00f3 Farmac\u00e8utica comen\u00e7a quan el pacient lliura la recepta, ja que \u00e9s necessari con\u00e8ixer els motius de la prescripci\u00f3 per aconseguir una perfecta adaptaci\u00f3 del medicament. Quan es lliura el f\u00e0rmac \u00e9s fonamental dedicar un temps a explicar com ha de ser l’administraci\u00f3. I, posteriorment, m\u00e9s que amb altres medicaments, \u00e9s imprescindible el seguiment. Tant l’elaboraci\u00f3 del f\u00e0rmac com explicar correctament al pacient com prendre-ho contribueix al seu torn a aconseguir la seva confian\u00e7a i aix\u00f2 fidelitza.\u00a0<\/p>\n

F\u00f3rmula 2015, objectius comuns
<\/strong>Un altre dels projectes en marxa per a la divulgaci\u00f3 d’informaci\u00f3 rigorosa sobre formulaci\u00f3 magistral per aconseguir la participaci\u00f3 del metge i familiaritzar a la societat amb aquest tipus de prescripci\u00f3 \u00e9s \u201cF\u00f3rmula 2015\u201d. Es va presentar a finals de 2010 i \u00e9s fruit de la col\u00b7laboraci\u00f3 entre Aprofarm i l’Associaci\u00f3 Espanyola de Farmac\u00e8utics Formulistes (AEFF), juntament amb el suport dels COF de Barcelona i Madrid. De moment, a trav\u00e9s de 60 sessions, han arribat ja a m\u00e9s d’1.000 prescriptors.\u00a0<\/p>\n

\u00a0\u00a0
Per a m\u00e9s informaci\u00f3<\/strong>:\u00a0
Aprofarm: Montserrat Torrell \u2013\u00a0montse@aprofarm.org<\/a>\u00a0
Tfn.: 93 322 22 11\u00a0
Departament de Comunicaci\u00f3 Col\u00b7legi de Farmac\u00e8utics de Barcelona\u00a0
Tfn.: 93 244 07 28 \/18 \u2013 E-mail:\u00a0premsa@cofb.net<\/a><\/p>\n

\u00a0\u00a0\u2022 Oncologia, pediatria, geriatria i situacions cl\u00edniques complexes troben resposta en el medicament personalitzat a m\u00faltiples\u00a0llacunes terap\u00e8utiques\u00a0\u2022 De tot aix\u00f2 es va parlar en el\u00a0IV F\u00f2rum Aprofarm, celebrat la passada setmana a Barcelona amb la col\u00b7laboraci\u00f3 del COFB i m\u00e9s de 220 assistents, sota el t\u00edtol \u201cFormulaci\u00f3 de futur: ter\u00e0pies individualitzades\u201d\u00a0\u2022 En l\u2019edici\u00f3 d\u2019enguany es va presentar\u00a0el primer Formulari adre\u00e7at a metges d\u2019Atenci\u00f3 Prim\u00e0ria\u00a0amb m\u00e9s de 150 f\u00f3rmules\u00a0Barcelona, maig de 2011.- \u201cMolts problemes que es podrien resoldre amb la formulaci\u00f3 magistral no s’estan resolent per desconeixement\u201d. Aix\u00ed ho explica Francesc Llamb\u00ed, president d\u2019Aprofarm, l’associaci\u00f3 de formuladors magistrals que aquest mes de maig ha celebrat la IV edici\u00f3 del F\u00f2rum Aprofarm amb la col\u00b7laboraci\u00f3 del Col\u00b7legi de Farmac\u00e8utics de Barcelona i l’assist\u00e8ncia de m\u00e9s de 220 professionals. L’objectiu: apropar als professionals les solucions terap\u00e8utiques que pot oferir el medicament personalitzat.\u00a0En la inauguraci\u00f3 de la trobada, Llamb\u00ed va insistir en la necessitat de mostrar la formulaci\u00f3 magistral com un recurs terap\u00e8utic a utilitzar. Per la seva banda, Jordi De Dalmases, president del Col\u00b7legi de Farmac\u00e8utics de Barcelona, va parlar de la necessitat de \u201ctreballar i acaronar conjuntament la formulaci\u00f3 magistral\u201d. I, en aquest sentit, tots dos van destacar el treball que s’est\u00e0 realitzant des del Consejo General de Colegios Farmac\u00e9uticos amb diversos projectes oberts en el marc del grup de treball del que forma part De Dalmases.\u00a0\u201cEl farmac\u00e8utic pot aportar solucions a problemes relacionats amb el subministrament de medicaments en pediatria, geriatria, insufici\u00e8ncies renals i hep\u00e0tiques, situacions cl\u00edniques complicades, problemes de degluci\u00f3, coordinaci\u00f3, malalts terminals\u2026 per\u00f2 per a aix\u00f2 \u00e9s necessari que tant farmac\u00e8utics com metges coneguin el que pot oferir la formulaci\u00f3 magistral\u201d, insisteix Llamb\u00ed.\u00a0Amb aquest mateix objectiu es va presentar en el marc del F\u00f2rum el primer formulari dirigit a metges d’atenci\u00f3 prim\u00e0ria, amb m\u00e9s de 150 f\u00f3rmules a les quals accedir per patologia o principi actiu i que poden donar resposta a m\u00faltiples pacients amb necessitats espec\u00edfiques. Un \u201cFormulari b\u00e0sic d’Atenci\u00f3 Prim\u00e0ria\u201d, que ja est\u00e0 disponible a trav\u00e9s de la xarxa [www.cofb.org\/web\/guest\/als-professionals-sanitaris].\u00a0A Espanya el volum de dispensacions de f\u00f3rmules magistrals \u00e9s inferior a l\u20191%, lluny de les xifres d’altres pa\u00efsos com Holanda, EUA o Brasil. No obstant aix\u00f2, en \u00e0mbits com les UCIs de neonatologia, entre el 35 i 40% dels medicaments s\u00f3n f\u00f3rmules magistrals. \u201cNo es tracta d’estendre el seu \u00fas de forma indiscriminada per\u00f2 s\u00ed de donar una resposta adequada a aquelles patologies que ho requereixin\u201d, explica Llamb\u00ed. C\u00e0ncer i prec\u00e0ncer cutani, formulaci\u00f3 pedi\u00e0trica, dermatologia i cosm\u00e8tica, podologia, veterin\u00e0ria\u2026 s\u00f3n alguns exemples i sobre tots ells es va parlar en les diferents taules rodones que va acollir la trobada a c\u00e0rrec de m\u00e9s de 25 especialistes de les diverses \u00e0rees.\u00a0\u201cLa formulaci\u00f3 magistral est\u00e0 estretament relacionada amb l’Atenci\u00f3 Farmac\u00e8utica\u201dEn les taules rodones es va abordar tamb\u00e9 un nou enfocament: els punts de connexi\u00f3 entre formulaci\u00f3 i atenci\u00f3 farmac\u00e8utica. Amb els medicaments individualitzats l’Atenci\u00f3 Farmac\u00e8utica comen\u00e7a quan el pacient lliura la recepta, ja que \u00e9s necessari con\u00e8ixer els motius de la prescripci\u00f3 per aconseguir una perfecta adaptaci\u00f3 del medicament. Quan es lliura el f\u00e0rmac \u00e9s fonamental dedicar un temps a explicar com ha de ser l’administraci\u00f3. I, posteriorment, m\u00e9s que amb altres medicaments, \u00e9s imprescindible el seguiment. Tant l’elaboraci\u00f3 del f\u00e0rmac com explicar correctament al pacient com prendre-ho contribueix al seu torn a aconseguir la seva confian\u00e7a i aix\u00f2 fidelitza.\u00a0F\u00f3rmula 2015, objectius comunsUn altre dels projectes en marxa per a la divulgaci\u00f3 d’informaci\u00f3 rigorosa sobre formulaci\u00f3 magistral per aconseguir la participaci\u00f3 del metge i familiaritzar a la societat amb aquest tipus de prescripci\u00f3 \u00e9s \u201cF\u00f3rmula 2015\u201d. Es va presentar a finals de 2010 i \u00e9s fruit de la col\u00b7laboraci\u00f3 entre Aprofarm i l’Associaci\u00f3 Espanyola de Farmac\u00e8utics Formulistes (AEFF), juntament amb el suport dels COF de Barcelona i Madrid. De moment, a trav\u00e9s de 60 sessions, han arribat ja a m\u00e9s d’1.000 prescriptors.\u00a0\u00a0\u00a0Per a m\u00e9s informaci\u00f3:\u00a0Aprofarm: Montserrat Torrell \u2013\u00a0montse@aprofarm.org\u00a0Tfn.: 93 322 22 11\u00a0Departament de Comunicaci\u00f3 Col\u00b7legi de Farmac\u00e8utics de Barcelona\u00a0Tfn.: 93 244 07 28 \/18 \u2013 E-mail:\u00a0premsa@cofb.net\u00a0\u00a0COFB.ORG<\/p>\n","protected":false},"excerpt":{"rendered":"

\u00a0 \u00a0\u2022 Oncologia, pediatria, geriatria i situacions cl\u00edniques complexes troben resposta en el medicament personalitzat a m\u00faltiples\u00a0llacunes terap\u00e8utiques\u00a0 \u2022 De tot aix\u00f2 es va parlar en el\u00a0IV F\u00f2rum Aprofarm, celebrat la passada setmana a Barcelona amb la col\u00b7laboraci\u00f3 del COFB i m\u00e9s de 220 assistents, sota el t\u00edtol \u201cFormulaci\u00f3 de […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1060,1066],"tags":[],"class_list":["post-77649","post","type-post","status-publish","format-standard","hentry","category-notes-premsa","category-sense-categoria-ca"],"yoast_head":"\nHi ha obstacles terap\u00e8utics que no s'estan resolent per una infrautilitzaci\u00f3 de la formulaci\u00f3 magistral - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2011\/05\/26\/hi-ha-obstacles-terapeutics-que-no-sestan-resolent-per-una-infrautilitzacio-de-la-formulacio-magistral\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hi ha obstacles terap\u00e8utics que no s'estan resolent per una infrautilitzaci\u00f3 de la formulaci\u00f3 magistral - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"\u00a0 \u00a0\u2022 Oncologia, pediatria, geriatria i situacions cl\u00edniques complexes troben resposta en el medicament personalitzat a m\u00faltiples\u00a0llacunes terap\u00e8utiques\u00a0 \u2022 De tot aix\u00f2 es va parlar en el\u00a0IV F\u00f2rum Aprofarm, celebrat la passada setmana a Barcelona amb la col\u00b7laboraci\u00f3 del COFB i m\u00e9s de 220 assistents, sota el t\u00edtol \u201cFormulaci\u00f3 de […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2011\/05\/26\/hi-ha-obstacles-terapeutics-que-no-sestan-resolent-per-una-infrautilitzacio-de-la-formulacio-magistral\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2011-05-26T10:59:00+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2011\/05\/26\/hi-ha-obstacles-terapeutics-que-no-sestan-resolent-per-una-infrautilitzacio-de-la-formulacio-magistral\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2011\/05\/26\/hi-ha-obstacles-terapeutics-que-no-sestan-resolent-per-una-infrautilitzacio-de-la-formulacio-magistral\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Hi ha obstacles terap\u00e8utics que no s’estan resolent per una infrautilitzaci\u00f3 de la formulaci\u00f3 magistral\",\"datePublished\":\"2011-05-26T10:59:00+00:00\",\"dateModified\":\"2011-05-26T10:59:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2011\/05\/26\/hi-ha-obstacles-terapeutics-que-no-sestan-resolent-per-una-infrautilitzacio-de-la-formulacio-magistral\/\"},\"wordCount\":1516,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"articleSection\":[\"Notes de premsa\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2011\/05\/26\/hi-ha-obstacles-terapeutics-que-no-sestan-resolent-per-una-infrautilitzacio-de-la-formulacio-magistral\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2011\/05\/26\/hi-ha-obstacles-terapeutics-que-no-sestan-resolent-per-una-infrautilitzacio-de-la-formulacio-magistral\/\",\"name\":\"Hi ha obstacles terap\u00e8utics que no s'estan resolent per una infrautilitzaci\u00f3 de la formulaci\u00f3 magistral - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"datePublished\":\"2011-05-26T10:59:00+00:00\",\"dateModified\":\"2011-05-26T10:59:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2011\/05\/26\/hi-ha-obstacles-terapeutics-que-no-sestan-resolent-per-una-infrautilitzacio-de-la-formulacio-magistral\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2011\/05\/26\/hi-ha-obstacles-terapeutics-que-no-sestan-resolent-per-una-infrautilitzacio-de-la-formulacio-magistral\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2011\/05\/26\/hi-ha-obstacles-terapeutics-que-no-sestan-resolent-per-una-infrautilitzacio-de-la-formulacio-magistral\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hi ha obstacles terap\u00e8utics que no s’estan resolent per una infrautilitzaci\u00f3 de la formulaci\u00f3 magistral\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hi ha obstacles terap\u00e8utics que no s'estan resolent per una infrautilitzaci\u00f3 de la formulaci\u00f3 magistral - Col\u00b7legi de Farmac\u00e8utics de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2011\/05\/26\/hi-ha-obstacles-terapeutics-que-no-sestan-resolent-per-una-infrautilitzacio-de-la-formulacio-magistral\/","og_locale":"ca_ES","og_type":"article","og_title":"Hi ha obstacles terap\u00e8utics que no s'estan resolent per una infrautilitzaci\u00f3 de la formulaci\u00f3 magistral - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"\u00a0 \u00a0\u2022 Oncologia, pediatria, geriatria i situacions cl\u00edniques complexes troben resposta en el medicament personalitzat a m\u00faltiples\u00a0llacunes terap\u00e8utiques\u00a0 \u2022 De tot aix\u00f2 es va parlar en el\u00a0IV F\u00f2rum Aprofarm, celebrat la passada setmana a Barcelona amb la col\u00b7laboraci\u00f3 del COFB i m\u00e9s de 220 assistents, sota el t\u00edtol \u201cFormulaci\u00f3 de […]","og_url":"https:\/\/novaorg.cofb.net\/2011\/05\/26\/hi-ha-obstacles-terapeutics-que-no-sestan-resolent-per-una-infrautilitzacio-de-la-formulacio-magistral\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2011-05-26T10:59:00+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrit per":"wpAdminCofbOrg","Temps estimat de lectura":"7 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2011\/05\/26\/hi-ha-obstacles-terapeutics-que-no-sestan-resolent-per-una-infrautilitzacio-de-la-formulacio-magistral\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2011\/05\/26\/hi-ha-obstacles-terapeutics-que-no-sestan-resolent-per-una-infrautilitzacio-de-la-formulacio-magistral\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Hi ha obstacles terap\u00e8utics que no s’estan resolent per una infrautilitzaci\u00f3 de la formulaci\u00f3 magistral","datePublished":"2011-05-26T10:59:00+00:00","dateModified":"2011-05-26T10:59:00+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2011\/05\/26\/hi-ha-obstacles-terapeutics-que-no-sestan-resolent-per-una-infrautilitzacio-de-la-formulacio-magistral\/"},"wordCount":1516,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"articleSection":["Notes de premsa"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2011\/05\/26\/hi-ha-obstacles-terapeutics-que-no-sestan-resolent-per-una-infrautilitzacio-de-la-formulacio-magistral\/","url":"https:\/\/novaorg.cofb.net\/2011\/05\/26\/hi-ha-obstacles-terapeutics-que-no-sestan-resolent-per-una-infrautilitzacio-de-la-formulacio-magistral\/","name":"Hi ha obstacles terap\u00e8utics que no s'estan resolent per una infrautilitzaci\u00f3 de la formulaci\u00f3 magistral - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"datePublished":"2011-05-26T10:59:00+00:00","dateModified":"2011-05-26T10:59:00+00:00","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2011\/05\/26\/hi-ha-obstacles-terapeutics-que-no-sestan-resolent-per-una-infrautilitzacio-de-la-formulacio-magistral\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2011\/05\/26\/hi-ha-obstacles-terapeutics-que-no-sestan-resolent-per-una-infrautilitzacio-de-la-formulacio-magistral\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2011\/05\/26\/hi-ha-obstacles-terapeutics-que-no-sestan-resolent-per-una-infrautilitzacio-de-la-formulacio-magistral\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Hi ha obstacles terap\u00e8utics que no s’estan resolent per una infrautilitzaci\u00f3 de la formulaci\u00f3 magistral"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"\u00a0 \u00a0\u2022 Oncologia, pediatria, geriatria i situacions cl\u00edniques complexes troben resposta en el medicament personalitzat a m\u00faltiples\u00a0llacunes terap\u00e8utiques\u00a0 \u2022 De tot aix\u00f2 es va parlar en el\u00a0IV F\u00f2rum Aprofarm, celebrat la passada setmana a Barcelona amb la col\u00b7laboraci\u00f3 del COFB i m\u00e9s de 220 assistents, sota el t\u00edtol \u201cFormulaci\u00f3 de […]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/77649","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/comments?post=77649"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/77649\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media?parent=77649"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/categories?post=77649"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/tags?post=77649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}